| Keywords: |
review; doxorubicin; interferon; antineoplastic agents; combined modality therapy; neurotoxicity; neoplasms; liver toxicity; nephrotoxicity; gastrointestinal symptom; drug administration schedule; cyclophosphamide; cancer therapy; vinblastine; gastrointestinal toxicity; kidney; immunotherapy; gamma interferon; eflornithine; cardiotoxicity; recombinant proteins; killer cells, natural; polyinosinic polycytidylic acid; carboxymethylcellulose polycytidylic polyinosinic acid polylysine; carboxymethylcellulose; interferon inducers; poly i-c; polylysine; drug dose; dye; antibodies; alpha2a interferon; adjuvants, immunologic; pyrimidine derivative; influenza; beta interferon; heart; adverse drug reaction; therapy; clinical trials; nervous system; recombinant alpha2a interferon; recombinant alpha2b interferon; electrolyte balance; drug evaluation; intoxication; mepacrine; digestive system; terminology; interferon inducing agent; bacterial toxin; interferons; human; support, non-u.s. gov't; support, u.s. gov't, p.h.s.; recombinant alpha2 interferon; alphan1 interferon; tilorone; poly(inosinic acid cytidylic acid lysine)
|
